News | October 04, 2025
Lupin launches Liraglutide injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Subscribe To Our Newsletter & Stay Updated
